(MedPage Today) — VEGF inhibitors, such as ranibizumab (Lucentis) or bevacizumab (Avastin), may improve vision in patients with diabetic macular edema, but more research is needed, according to a Medicare advisory panel.
Month: March 2012
Eye Examination for ARMD: Macular Degeneration
Macular degeneration can only be diagnosed when there are symptoms and findings of the disease. Routine examination in normal situations may not be necessary.
Exonhit 2011 consolidated revenues decrease to € 5.0 million
The Management Board of Exonhit SA met on March 21 to close the consolidated financial accounts for the year ending on December 31, 2011. These accounts were audited by the auditors and verified by the Supervisory Board.
New Device Effective in Trabeculotomy
A case series from the Mayo clinic supports the use of the Trabectome device in ab interno trabeculotomy. Risk factors for failure, such as primary open-angle glaucoma, may dictate patient selection. Medscape Medical News
Nonpungent capsaicin analogs (capsinoids) increase energy expenditure
By: Yoneshiro
Diabetic Retinopathy: A Team Approach
The progression of diabetic retinopathy is amenable to treatment, so don’t neglect eye health in your patients with diabetes. Medscape Ophthalmology
US FDA grants "orphan drug" status for verteporfin (Visudyne) for central serous chorioretinopathy
Source: GlobeNewswire, BioSpace
Area: News
The US Food and Drug Administration (FDA) has granted “orphan drug” status for verteporfin (Visudyne) for the potential treatment of chronic or recurrent central serous chorioretinopathy (CSC).
Glaucoma Prevented By Targeted X-Ray Treatment In Mice
Jackson Laboratory researchers have demonstrated that a single, targeted x-ray treatment of an individual eye in young, glaucoma-prone mice provided that eye with apparently life-long and typically complete protection from glaucoma. In research publish…
News From The Journal Of Clinical Investigation: March 19, 2012
A clearer understanding of glaucoma Glaucoma is one of the leading causes of vision loss and blindness worldwide. In glaucoma patients, the optic nerve, which relays information from the eye to the brain, is damaged, though the molecular cause of nerv…
Brilliant Blue G Recalled Because of Fungal Contamination
A pharmacy in Florida is recalling lots of Brilliant Blue G ophthalmic solution because of the development of fungal endophthalmitis in some patients. News Alerts
Clinical Notes: Foodborne Illness Toll Soars
(MedPage Today) — Reports from a CDC-sponsored conference painted a grim picture of increasing deaths and illnesses from ingested pathogens over the past decade. Also this week: kids skip out on allergy treatments.
Retinopathy Tied to Cognitive Decline (CME/CE)
(MedPage Today) — The eye of the patient may hold clues to the risk of dementia, researchers reported.
DMEI chooses ifa EMR v6 as its future Electronic Medical Record system
ifa united i-tech, a U.S. subsidiary of ifa Systems AG, the global leader for IT solutions in ophthalmology, announced that the Dean McGee Eye Institute (DMEI) selected ifa EMR v6 as its future Electronic Medical Record (EMR) system.
Einstein members celebrate 2012 Match Day
Members of Albert Einstein College of Medicine of Yeshiva University’s graduating class celebrated another strong year for residency placements in competitive specialties and prestigious programs at this year’s Match Day. Representing the culmination o…
Should All African Americans Get Glaucoma Screening?
Screening middle-aged African Americans for glaucoma may prevent some from losing their vision, but the benefits are modest and costly, suggests a new study. Reuters Health Information
Moorfields Pharmaceuticals recalls selected batches of bevacizumab intravitreal injection 1.25mg/0.05ml following reports of suspected sterile endophthalmitis
Source: MHRA
Area: News
Moorfields Pharmaceuticals has issued a precautionary recall of selected lots (see list of batch numbers in document at link below) of bevacizumab intravitreal injection 1.25mg/0.05ml following a number of reports of suspected …
Blood Vessel Disease Of Retina May Be Marker Of Cognitive Decline
Women 65 or older who have even mild retinopathy, a disease of blood vessels in the retina, are more likely to have cognitive decline and related vascular changes in the brain, according to a multi-institutional study led by scientists at the Universit…
ThromboGenics, Alcon collaborate to commercialize ocriplasmin outside the US
ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces today that it has entered into an agreement with Alcon (a division of Novartis), the global leader in eyecare, for the commercialization of o…
Stem Cells in Ophthalmology Update 18: Stem Cells Inc. Demonstrates That its Human Neural Stem Cells Preserve Vision – Gets FDA Authorization to Initiate Clinical Trial for Dry AMD
On January 30, 2012, Stem Cells Inc. announced the publication of preclinical data demonstrating that its proprietary HuCNS-SCr cells (purified human neural stem cells) protect host photoreceptors and preserve vision in an animal model of retinal disea…
Retinopathy May Signal Impending Cognitive Decline
A study links retinopathy to subsequent cognitive impairment and ischemic brain changes in healthy older women. Medscape Medical News